GlassScriptPhysician profile
Henry B Ayiku
NPI 1477509404
$2,047.47
in general payments reported to CMS, 2019-2025
23 companies · $793 in 2025
The $793 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.17 · 2021: $68.51 · 2022: $208 · 2023: $334 · 2024: $632 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,685 · Education: $72.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,685.18 |
| Education | $72.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $494.77 | 2021-2024 | Veltassa |
| Aurinia Pharma U.S., INC. | $215.63 | 2022-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $194.30 | 2022-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $192.50 | 2024-2025 | |
| Travere Therapeutics, INC. | $169.52 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $91.60 | 2023-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $79.31 | 2022-2024 | Jynarque |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $78.35 | 2024-2025 | |
| Novo Nordisk INC | $71.68 | 2024-2025 | Rivfloza |
| Alexion Pharmaceuticals, INC. | $56.27 | 2022-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $49.24 | 2022-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.16 | 2025 | Jardiance |
| Ardelyx, INC. | $46.19 | 2023-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $45.92 | 2025 | |
| Amgen INC. | $43.03 | 2025 | Tavneos |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $24.78 | 2023 | Rayaldee |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Lilly USA, LLC | $22.95 | 2024 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $22.10 | 2023 | |
| Scpharmaceuticals INC. | $22.00 | 2025 | |
| Alnylam Pharmaceuticals INC. | $22.00 | 2023 | Givlaari |
| Horizon Therapeutics Plc | $20.39 | 2023 | Krystexxa |
| Nxstage Medical, INC. | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Ayiku listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.